These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 9307304

  • 1. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
    Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD.
    Cancer Res; 1997 Sep 15; 57(18):4130-40. PubMed ID: 9307304
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ.
    Cancer Res; 1995 Jul 15; 55(14):3140-8. PubMed ID: 7606735
    [Abstract] [Full Text] [Related]

  • 3. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF, Reist CJ, Bigner DD, Zalutsky MR.
    Cancer Res; 2000 Aug 15; 60(16):4453-60. PubMed ID: 10969792
    [Abstract] [Full Text] [Related]

  • 4. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.
    Cancer Res; 2000 Jun 01; 60(11):3081-7. PubMed ID: 10850460
    [Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW.
    Cancer Res; 2003 Jun 15; 63(12):3154-61. PubMed ID: 12810643
    [Abstract] [Full Text] [Related]

  • 6. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
    Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I.
    Clin Cancer Res; 1995 Aug 15; 1(8):859-64. PubMed ID: 9816055
    [Abstract] [Full Text] [Related]

  • 7. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT, Reist CJ, Foulon CF, Lorimer IA, Archer G, Pegram CN, Pastan I, Zalutsky MR, Bigner DD.
    Clin Cancer Res; 1999 Jun 15; 5(6):1539-49. PubMed ID: 10389943
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.
    Clin Cancer Res; 2004 Oct 01; 10(19):6732-43. PubMed ID: 15475464
    [Abstract] [Full Text] [Related]

  • 9. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR.
    Cancer Res; 1995 Oct 01; 55(19):4375-82. PubMed ID: 7671250
    [Abstract] [Full Text] [Related]

  • 10. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.
    Cancer Res; 2006 Jan 15; 66(2):867-74. PubMed ID: 16424019
    [Abstract] [Full Text] [Related]

  • 11. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids.
    Grill J, Van Beusechem VW, Van Der Valk P, Dirven CM, Leonhart A, Pherai DS, Haisma HJ, Pinedo HM, Curiel DT, Gerritsen WR.
    Clin Cancer Res; 2001 Mar 15; 7(3):641-50. PubMed ID: 11297260
    [Abstract] [Full Text] [Related]

  • 12. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee WK.
    Cancer Res; 2001 Jul 15; 61(14):5349-54. PubMed ID: 11454673
    [Abstract] [Full Text] [Related]

  • 13. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.
    Clin Cancer Res; 2005 Sep 01; 11(17):6390-9. PubMed ID: 16144944
    [Abstract] [Full Text] [Related]

  • 14. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
    Shankar S, Vaidyanathan G, Kuan CT, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2006 Jan 01; 33(1):101-10. PubMed ID: 16459265
    [Abstract] [Full Text] [Related]

  • 15. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies.
    Yang W, Wu G, Barth RF, Swindall MR, Bandyopadhyaya AK, Tjarks W, Tordoff K, Moeschberger M, Sferra TJ, Binns PJ, Riley KJ, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ.
    Clin Cancer Res; 2008 Feb 01; 14(3):883-91. PubMed ID: 18245552
    [Abstract] [Full Text] [Related]

  • 16. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR.
    Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM.
    Cancer Res; 2001 Jul 15; 61(14):5355-61. PubMed ID: 11454674
    [Abstract] [Full Text] [Related]

  • 17. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.
    Yang W, Barth RF, Wu G, Kawabata S, Sferra TJ, Bandyopadhyaya AK, Tjarks W, Ferketich AK, Moeschberger ML, Binns PJ, Riley KJ, Coderre JA, Ciesielski MJ, Fenstermaker RA, Wikstrand CJ.
    Clin Cancer Res; 2006 Jun 15; 12(12):3792-802. PubMed ID: 16778107
    [Abstract] [Full Text] [Related]

  • 18. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
    Yang B, Chen J, Zhang X, Cao J.
    Auris Nasus Larynx; 2009 Dec 15; 36(6):682-7. PubMed ID: 19427146
    [Abstract] [Full Text] [Related]

  • 19. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR.
    Cancer Res; 1997 Apr 15; 57(8):1510-5. PubMed ID: 9108453
    [Abstract] [Full Text] [Related]

  • 20. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.
    Clin Cancer Res; 2006 Sep 01; 12(17):5064-73. PubMed ID: 16951222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.